Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors
试验速览
- 阶段
- 4 期
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Mean diffusivity
研究概览
简要总结
Background:
Conclusive evidence states that the serotonergic system mediates neuroplasticity from early embryonic development until brain maturation in adulthood. This study aims to demonstrate that selective serotonin reuptake inhibitors (SSRIs) enhance learning-dependent neuroplasticity in vivo, hereby contributing to the investigators understanding of the mechanism of action of therapy with SSRIs.
Objectives:
- To prove a positive influence of SSRIs on structural remodeling during learning, reflected by enhancements of gray and white matter microstructure, connectivity and functionality in brain regions involved in learning processes.
- To show that this effect is topologically specific, i.e. that enhancements of plasticity markers are found in different regions depending on their involvement during the performance of specific learning tasks.
Study design:
Randomized, double-blind, placebo-controlled, longitudinal mono-center study. 80 healthy subjects will undergo three MRI scanning sessions: 1. baseline, at study entry, 2. after 3 weeks of facial/emotional (n=40) or Chinese character-meaning learning (n=40) and 3. after 3 weeks learning of new associations under administration of an SSRI or placebo.
Methods:
MRI measurements will be performed on a 3 Tesla PRISMA MAGNETOM MR scanner. Changes in gray matter microstructure will be assessed using high-resolution structural MRI and analyzed with voxel-based morphometry (VBM). Diffusion tensor imaging (DTI) enables non-invasive investigation of neuroplasticity in the human brain based on the reduction in mean diffusivity associated with swelling of astrocytes after increased synaptic activity. Resting-state functional MRI (fMRI) will allow for the measurement of changes in functional coupling between brain regions, and fMRI during tasks will assess differential activity in brain regions during learning.
Relevance and implications:
This study aims to provide evidence that SSRIs facilitate cytoarchitectonical restructuring. In addition to expanding the investigators current knowledge on the trophic effects of SSRIs, the results of this study will also elucidate interactions between the serotonergic system and changes to neuronal networks during learning as well as their behavioral consequences. By probing the neurobiological correlates of the antidepressant and anti-anxiety effects of SSRIs, this study will provide a rationale for targeted interventions that harness the neuroplasticity enhancing properties of SSRIs to facilitate therapeutic processes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years(Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •General health based on medical history, physical examination and structured clinical interview for DSM-IV (SCID)
- •Willingness and competence to sign the informed consent form
- •Right-handedness
- •Non-smoker, and non-alcohol drinker
排除标准
- •Any medical, psychiatric or neurological illness
- •Current or former substance abuse
- •Any implant or stainless steel graft or any other contraindications for MRI
- •First degree relatives with a history of psychiatric illness or substance abuse
- •Color blindness, any Chinese language skills
- •Failure to comply with the study protocol or to follow the instructions of the investigating team
- •Lifetime use of SSRIs or related psychotropic agents
- •Non-Caucasian
研究组 & 干预措施
SSRI treatment
Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
干预措施: Escitalopram (Drug)
SSRI treatment
Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
干预措施: 3xMR scan (fMRI, DTI, strucutral MRI) (Other)
SSRI treatment
Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
干预措施: Association learning paradigm (Behavioral)
SSRI treatment
Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
干预措施: Association re-learning paradigm (Behavioral)
Placebo treatment
Subjects will receive 21 days of placebo treatment while performing learning paradigms.
干预措施: Placebo (Drug)
Placebo treatment
Subjects will receive 21 days of placebo treatment while performing learning paradigms.
干预措施: 3xMR scan (fMRI, DTI, strucutral MRI) (Other)
Placebo treatment
Subjects will receive 21 days of placebo treatment while performing learning paradigms.
干预措施: Association learning paradigm (Behavioral)
Placebo treatment
Subjects will receive 21 days of placebo treatment while performing learning paradigms.
干预措施: Association re-learning paradigm (Behavioral)
结局指标
主要结局
Mean diffusivity
时间窗: 21 days
diffusion tensor imaging
Gray matter volume
时间窗: 21 days
voxel based morphometry (T1 weighted MPRAGE sequence)
次要结局
- BOLD signal(21 days)
研究者
Rupert Lanzenberger
Prof MD
Medical University of Vienna
